Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature.
(2009) In Journal of Clinical Endocrinology and Metabolism Nov 11. p.483-490- Abstract
- Context: Weight-based growth hormone (GH) dosing results in a wide variation in growth response in children with GH deficiency (GHD) or idiopathic short stature (ISS). Objective: The hypothesis tested was whether individualized GH doses, based on variation in GH responsiveness estimated by a prediction model, reduced variability in growth response around a set height target compared with a standardized weight-based dose. Setting: 153 short prepubertal children diagnosed with isolated GHD or ISS (n=43) and >/=1 SDS below mid-parental height standard deviation score(MPHSDS) were included in this 2-year multicenter study. Intervention: The children were randomized to either a standard (43 microg/kg/d) or an individualized GH dose (17-100... (More)
- Context: Weight-based growth hormone (GH) dosing results in a wide variation in growth response in children with GH deficiency (GHD) or idiopathic short stature (ISS). Objective: The hypothesis tested was whether individualized GH doses, based on variation in GH responsiveness estimated by a prediction model, reduced variability in growth response around a set height target compared with a standardized weight-based dose. Setting: 153 short prepubertal children diagnosed with isolated GHD or ISS (n=43) and >/=1 SDS below mid-parental height standard deviation score(MPHSDS) were included in this 2-year multicenter study. Intervention: The children were randomized to either a standard (43 microg/kg/d) or an individualized GH dose (17-100 microg/kg/d). Main outcome measure: Deviation of HeightSDS from individual MPHSDS (diffMPHSDS). The primary endpoint was difference in the range of 'diffMPHSDS' between the two groups. Results: diffMPHSDS range was reduced by 32% in the individualized-dose group relative to the standard-dose group (p<0.003), whereas the mean 'diffMPHSDS' was equal: -0.42+/-0.46 and -0.48+/-0.67, respectively. Gain in HeightSDS 0-2 yrs was equal for the GH-deficient and the ISS groups; 1.31+/-0.47 and 1.36+/-0.47, respectively, when ISS was classified on the basis of maximum GH peak on the arginine-insulin tolerance test or 24h profile. Conclusion: Individualized GH doses during catch-up growth significantly reduces the proportion of unexpectedly good and poor responders around a predefined individual growth target and results in equal growth responses in children with GHD and ISS. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1271589
- author
- Kriström, Berit ; Aronson, A Stefan ; Dahlgren, Jovanna ; Gustafsson, Jan ; Halldin, Maria ; Ivarsson, Sten LU ; Nilsson, Nils-Eric LU ; Svensson, Johan LU ; Tuvemo, Torsten and Albertsson-Wikland, Kerstin
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Clinical Endocrinology and Metabolism
- volume
- Nov 11
- pages
- 483 - 490
- publisher
- Oxford University Press
- external identifiers
-
- wos:000263072700024
- pmid:19001519
- scopus:59749099510
- ISSN
- 1945-7197
- DOI
- 10.1210/jc.2008-1503
- language
- English
- LU publication?
- yes
- id
- 98da361f-9a7e-476b-be1b-b4ec261d3951 (old id 1271589)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19001519?dopt=Abstract
- date added to LUP
- 2016-04-04 09:28:04
- date last changed
- 2022-04-23 20:39:55
@article{98da361f-9a7e-476b-be1b-b4ec261d3951,
abstract = {{Context: Weight-based growth hormone (GH) dosing results in a wide variation in growth response in children with GH deficiency (GHD) or idiopathic short stature (ISS). Objective: The hypothesis tested was whether individualized GH doses, based on variation in GH responsiveness estimated by a prediction model, reduced variability in growth response around a set height target compared with a standardized weight-based dose. Setting: 153 short prepubertal children diagnosed with isolated GHD or ISS (n=43) and >/=1 SDS below mid-parental height standard deviation score(MPHSDS) were included in this 2-year multicenter study. Intervention: The children were randomized to either a standard (43 microg/kg/d) or an individualized GH dose (17-100 microg/kg/d). Main outcome measure: Deviation of HeightSDS from individual MPHSDS (diffMPHSDS). The primary endpoint was difference in the range of 'diffMPHSDS' between the two groups. Results: diffMPHSDS range was reduced by 32% in the individualized-dose group relative to the standard-dose group (p<0.003), whereas the mean 'diffMPHSDS' was equal: -0.42+/-0.46 and -0.48+/-0.67, respectively. Gain in HeightSDS 0-2 yrs was equal for the GH-deficient and the ISS groups; 1.31+/-0.47 and 1.36+/-0.47, respectively, when ISS was classified on the basis of maximum GH peak on the arginine-insulin tolerance test or 24h profile. Conclusion: Individualized GH doses during catch-up growth significantly reduces the proportion of unexpectedly good and poor responders around a predefined individual growth target and results in equal growth responses in children with GHD and ISS.}},
author = {{Kriström, Berit and Aronson, A Stefan and Dahlgren, Jovanna and Gustafsson, Jan and Halldin, Maria and Ivarsson, Sten and Nilsson, Nils-Eric and Svensson, Johan and Tuvemo, Torsten and Albertsson-Wikland, Kerstin}},
issn = {{1945-7197}},
language = {{eng}},
pages = {{483--490}},
publisher = {{Oxford University Press}},
series = {{Journal of Clinical Endocrinology and Metabolism}},
title = {{Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature.}},
url = {{http://dx.doi.org/10.1210/jc.2008-1503}},
doi = {{10.1210/jc.2008-1503}},
volume = {{Nov 11}},
year = {{2009}},
}